Roxithromycin

ApprovedSmall molecule

HHamamatsu University

Roxithromycin is one of 85 small molecule programs targeting Bronchiectasis. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

BronchiectasisActive, not recruiting

Androgenetic AlopeciaActive, not recruiting

Rheumatoid ArthritisActive, not recruiting

BronchiectasisPhase 3

Active, not recruiting

Androgenetic AlopeciaPreclinical

Active, not recruiting

Rheumatoid ArthritisApproved

Active, not recruiting

Competition

Competitive Landscape

791 competitors in Rheumatoid Arthritis

#DrugCompanyPhaseTrials

Roxithromycin

HHamamatsu University

Approved

1 2

Actemra

Enbrel

64 4

Remicade

OOrganon and Co

Preclinical

43 5

Actos

Takeda

Preclinical

2 6

Kineret

SSwedish Orphan Biovitrum

Preclinical

6 7

Velcade

SShilpa Grover, MD, MPH

Preclinical

2 8

Vancocin

HHikma Pharmaceuticals LLC

Preclinical

1 9

Cimzia

UCB

Preclinical

3 10

Circadin

NNeurim Pharmaceuticals Ltd.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Rheumatoid Arthritis1 trial

Treatment of Rheumatoid Arthritis With Roxithromycin

Completed·NNazilli State Hospital·Phase 4·NCT00439062·100 enrolled

Bronchiectasis1 trial

Effects of Roxithromycin on Quality of Life and Physiological Outcomes in Bronchiectasis

Completed·PPrince of Songkla University·Phase 3·NCT04122040·40 enrolled

Androgenetic Alopecia1 trial

The Effect of 0.5% Roxithromycin Lotion for Androgenetic Alopecia

Unknown status·HHamamatsu University·N/A·NCT00197379·20 enrolled

Unspecified1 trial

Bioequivalence Study of Two Roxithromycin Tablets in Healthy Subjects

Completed·TThe Affiliated Hospital Of Guizhou Medical University·Phase 1·NCT06798051·39 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Roxithromycin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Roxithromycin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Roxithromycin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hamamatsu University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: HHamamatsu University

Roxithromycin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Rheumatoid Arthritis1 trial

Bronchiectasis1 trial

Androgenetic Alopecia1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News